Broad physician adoption of a cannabis-derived epilepsy treatment is boosting sales for the only company with federal permission to sell cannabis products in the United States. London-based GW Pharmacetuticals told investors Monday that it notched $108 million in sales last quarter and $309 million for calendar 2019. The sales figures were released in advance of the company’s […]